PFE250103C16000
- 10.55
- 0.000.00%
Pfizer Newsroom
Truist Financial Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $32
The FDA states that GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) RSV vaccines must include warnings about the rare risk of paralysis.
The FDA stated that a vaccine produced by GlaxoSmithKline (GSK.US) and Pfizer (PFE.US) must include a warning about the potential increased risk of a rare neurological side effect.
Truist Financial Sticks to Its Buy Rating for Pfizer (PFE)
Pfizer Options Spot-On: On January 7th, 183.88K Contracts Were Traded, With 3.21 Million Open Interest
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
FDA Requires GSK and Pfizer Vaccines to Carry Rare Side Effect Warnings
GSK, Pfizer RSV Shots to Warn About Rare Neurological Disorder
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Express News | Pfizer Executives Descend on Donald Trump’s Mar-a-Lago for Planning Meeting - FT
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Moderna, Novavax and Other Vaccine Names Extend Gains Amid COVID/flu Concerns
PostEra Annonce L'extension À 610 Millions USD De Sa Collaboration Avec Pfizer Dans La Découverte De Médicaments Optimisée Par L'IA
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
Express News | Moderna up 7.5%, Novavax up 12.4%, Pfizer up 1.6%, U.S.-Listed Shares of CureVac up 10.6%
Express News | Shares of Vaccine Makers Rise in Early Trading
Why Pfizer (PFE) Is a Top Value Stock for the Long-Term
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death -- Barrons.com
Bird Flu Claims First U.S. Life in Louisiana